Clinical Trials Logo

Filter by:
NCT ID: NCT00597831 Completed - Depression Clinical Trials

Regulation of Intracerebral Pressure During Electroconvulsive Therapy

Start date: January 2008
Phase: N/A
Study type: Observational

The purpose of this study is to determine whether electroconvulsive therapy (ECT) has an influence on pressure within the human brain before, during and after ECT.

NCT ID: NCT00597207 Completed - Cardiac Arrest Clinical Trials

Circulation Improving Resuscitation Care (CIRC)

CIRC
Start date: January 2008
Phase: N/A
Study type: Interventional

During resuscitation of out of hospital cardiac arrest patients the use of a mechanical chest compression device Autopulse will improve survival compared to manual compressions.

NCT ID: NCT00595374 Completed - Diabetes Clinical Trials

Efficacy and Safety of Insulin Detemir in Type 1 Diabetes

Start date: December 2, 2003
Phase: Phase 3
Study type: Interventional

This trial is conducted in Europe. The aim of this trial is to compare the efficacy and safety of insulin detemir and insulin NPH in adults with type 1 diabetes on blood glucose control.

NCT ID: NCT00594048 Completed - Hypertension Clinical Trials

The Effects of Device-guided Breathing Exercises on Blood Pressure in Patients With Hypertension

Start date: January 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether breathing-exercises with the Resperate or listening to a discman with freely chosen music are effective in the treatment of hypertension

NCT ID: NCT00591136 Completed - Solid Tumors Clinical Trials

Phase I Study of Indibulin in Patients With Solid Tumors

Start date: April 2003
Phase: Phase 1
Study type: Interventional

Dose-finding and pharmacokinetic trial of orally administered Indibulin to patients with solid tumors.

NCT ID: NCT00586989 Completed - Barretts Esophagus Clinical Trials

Endoscopic Tri-Modal Imaging in Patients With Barrett's Esophagus

ETMI
Start date: December 2007
Phase: N/A
Study type: Observational

This study is being done to determine if a new endoscope will help doctors identify pre-cancer or early cancer lesions in patients who have Barrett's esophagus. This new endoscope allows the doctor to look at the lining of the esophagus in 3 different ways by modifying light.

NCT ID: NCT00578305 Completed - Clinical trials for Rheumatoid Arthritis

A Study of Rituximab (MabThera®/Rituxan®) in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate

SCORE
Start date: November 2007
Phase: Phase 3
Study type: Interventional

This 3 arm study assessed the efficacy of rituximab (MabThera®/Rituxan®) in the prevention of progression of structural joint damage in participants with active rheumatoid arthritis who had an inadequate clinical response to methotrexate. Participants were randomized to receive rituximab 500 mg intravenously (iv), rituximab 1000 mg iv, or placebo iv on days 1 and 15 every 24 weeks in the main study; all participants received concomitant methotrexate at a stable dose of 12.5-25 mg/week throughout the study. Further courses of rituximab were provided to eligible participants. Structural joint damage was assessed by magnetic resonance imaging (MRI) at baseline and at intervals during the study.

NCT ID: NCT00577837 Completed - Postmenopausal Clinical Trials

Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMD

Start date: April 2004
Phase: Phase 2
Study type: Interventional

A Multi-center, Active-controlled (5 mg daily risedronate), Double-blind, Randomized, Sequential Escalating Dose Study to Assess Safety, Pharmacokinetics and Efficacy of 100, 150, and 200 mg Oral Risedronate Administered Monthly for Six Months in Postmenopausal Women with Low Bone Mineral Density.

NCT ID: NCT00576758 Completed - Clinical trials for Non-Hodgkin's Lymphoma

GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma

Start date: January 2008
Phase: Phase 2
Study type: Interventional

This study will investigate the efficacy of weekly intravenous obinutuzumab [GA101 (RO5072759)] monotherapy, in patients with relapsed CD20+ indolent Non-Hodgkin's Lymphoma. Patients will be randomized to receive either GA101 or rituximab, given as four weekly infusions. At the conclusion of the initial trial patients may be eligible to continue therapy up to 24 months. The anticipated time on study treatment is 3- 24 months, and the target sample size is 100-500 individuals.

NCT ID: NCT00576563 Completed - Rectum Cancer Clinical Trials

Rectal Study: Value of Repeated FDG-PET-CT Scans in Rectal Cancer

Start date: March 2007
Phase: N/A
Study type: Interventional

To investigate the evolution of the 18F-deoxyglucose (FDG) uptake and the tumour characteristics determined in the plasma of patients with rectal cancer during and after radiotherapy or combined radiotherapy and chemotherapy. The changes of the FDG uptake of the primary tumour and the evolution of key tumour characteristics during radiotherapy alone or in combination with chemotherapy will be predictive for the pathological tumour response. Study hypothesis The changes of the FDG uptake of the primary tumour and the evolution of key tumour characteristics during radiotherapy alone or in combination with chemotherapy will be predictive for the pathological tumour response.